DEPARTMENT OF ORTHOPEDICS
Rocky Mountain Sarcoma Symposium
17-18 April 2026
Limelight Hotel | Boulder, CO
INNOVATION, COLLABORATION, AND HOPE
a Program harnesses the he CU Anschutz campus, rom the University of n’s Hospital Colorado, while accelerating lass research facilities with CU Boulder and the
the preferred sarcoma ain Region, with national h, expanding clinical pe to patients.
to welcome you to the 2nd Annual Rocky Mountain Sarcoma Symposium in beautiful Boulder, Colorado This year's program emphasizes clinical treatment and clinical trial updates in multidisciplinary sarcoma care We are honored to feature an impressive lineup of lecturers from the University of Colorado, as well as nationally-known guest lecturers
We extend our heartfelt gratitude to all the faculty members who have dedicated their time and expertise to make this event possible Your commitment to advancing sarcoma care through clinical excellence and groundbreaking research is truly inspiring. Thank you for your invaluable contributions and for being a beacon of hope for patients and families affected by sarcoma.
Steven
Thorpe, MD Co-Director
Breelyn Wilky, MD Co-Director
Erica Becker, PA Committee Member
Emily Blauel, MD Committee Member
Jenna Demedis MD, MS Committee Member
Qierra Brockman, PhD
Janai Carr-Ascher, MD, PhD
Jacob Cawley, MS, DVM
Michael Clay, MD Committee Member
Nathan Donaldson,DO Committee Member
Steven Dow, DVM, PhD
Michael Edwards, MD
Mark Greyson, MD
Patrick Grohar, MD, PhD
Ashleigh Guadagnolo, MD, MPH
Masanori Hayashi, MD Committee Member
Ryan Lanning, MD, PhD
Valerae O. Lewis, MD
Bennie Lindeque, MD, PhD
Robert Meguid, MD, MPH
Michael Monument, MD, MSc
Daniel Regan DVM, PhD, Committee Member
Jeff Rytlewski, MD
Jane Underdown, MD
Sujatha Venkataraman, PhD
Robert Maki, MD, PhD
Friday | 17 April
7:15 am – 8:00 am
Breakfast & Attendee Check-In
SARCOMA BASIC AND TRANSLATIONAL RESEARCH
8:00 am – 8:10 am
Welcome & Opening Remarks
Steven W. Thorpe, MD & Breelyn Wilky, MD – Course Directors
8:10 am – 8:50 am
Modeling Sarcoma Development to Identify New Therapeutic Opportunities
Janai Carr-Ascher, MD, PhD
8:50 am – 9:10 am
Lineage Plasticity in Sarcoma: A New Lens for Precision Medicine
Jacob Cawley, MS, DVM
9:10 am – 9:30 am
Targeting Metastatic Osteosarcoma in Dogs Using Chemokine Activated B7-H3 CAR T Cells
Steve Dow, DVM, PhD
9:30 am – 10:00 am
Expert Panel Discussion/Q&A: Janai Carr-Ascher, Jacob Cawley, Steve Dow
Moderator: Mas Hayashi, MD
10:00 am – 10:10 am BREAK
10:10 am – 10:30 am
Developing Circulating Epigenetic Biomarkers of Sarcoma Treatment of Response and Evasion
Qierra Brockman, PhD
10:30 am – 10:50 am
Durable Control of Ewing Sarcoma in Preclinical Models Using Next-Generation Gated CAR T Cells
Sujatha Venkataraman, PhD
10:50 am – 11:30 am
Dismantling Immune Suppression in Soft Tissue Sarcoma
Michael Monument, MD, MSc
11:30 am – 12:00 pm
Expert Panel Discussion/Q&A: Qierra Brockman, Sujatha Venkaterman, Michael Monument
Moderator: Dan Regan, DVM, PhD
12:00 pm – 1:00 pm LUNCH
AGENDA
UPDATES IN BONE SARCOMA: CHONDROSARCOMA
1:00 pm – 1:40 pm
From Tumor to Triumph: The Journey Back to Baseline After Pelvic Sarcoma
Valerae O. Lewis, MD
1:40 pm – 2:00 pm
Cartilaginous Neoplasms: Diagnostic and Molecular Updates
Michael Clay, MD
2:00 pm – 2:20 pm
Advances in Systemic Therapy for Chondrosarcoma
Jeff Rytlewski, MD
2:20 pm – 2:50 pm
Expert Panel Discussion/Q&A: Valerae Lewis, Michael Clay, Jeff Rytlewski
Moderator: Nathan Donaldson, MD
2:50 pm – 3:00 pm
BREAK
MANAGEMENT OF OLIGOMETASTATIC DISEASE
3:00 pm – 3:20 pm
Surgical Management of Oligometastatic Sarcoma to the Lungs
Robert Meguid, MD, MPH
3:20 pm – 3:40 pm
Less is More, More is Better: High Dose SBRT for Limited Sarcoma Pulmonary Metastatic Burden
Ryan Lanning, MD
3:40 pm – 4:00 pm
The One-Two Punch: Combination Systemic Therapies to Enhance Radiation in Sarcomas
Breelyn Wilky, MD
4:00 pm – 4:15 pm
Expert Panel Discussion/Q&A: Robert Meguid, Ryan Lanning, Breelyn Wilky
Moderator: Anthony Elias, MD
ROCKY
MOUNTAIN SARCOMA SYMPOSIUM KEYNOTE SPEAKER
4:15 pm – 5:00 pm
Keynote Address: How Might We Leverage Extranuclear DNA to Treat Sarcomas?
Robert Maki, MD, PhD
5:00 pm – 6:30 pm
Sponsor Reception | Cocktails and light hors d’oeuvres in sponsor foyer area
Saturday | 18 April
7:15 am – 8:00 am
Breakfast & Attendee Check-In
UPDATES IN MANAGEMENT OF SOFT TISSUE SARCOMA
8:00 am – 8:40 am
Hypofractionation for Soft Tissue Sarcoma: Are we racing ahead of the toxicity data?
Ashleigh Guadagnolo, MD, MPH
8:40 am – 9:00 am
Multidisciplinary Approach to Reconstruction after Sarcoma Resection: Restoring Form and Function
Steven W Thorpe, MD & Mark Greyson, MD
9:00 am – 9:30 am
Expert Panel Discussion/Q&A: Ashleigh Guadagnolo, Steven Thorpe, Mark Greyson
Moderator: Breelyn Wilky, MD
9:30 am – 9:40 am
Break
UPDATES IN PEDIATRIC AND ADOLESCENT AND YOUNG ADULT SARCOMA
9:40 am – 10:20 am
A Bench to Bedside and Back Again Approach to Therapeutic Development for Ewing Sarcoma
Patrick Grohar, MD, PhD
10:20 am – 10:40 am
From Predisposition to Prevention: Genetic Syndrome in Sarcomas
Michael Edwards, MD
10:40 am – 11:20 am
cMYC Amplification in Osteosarcoma
Jane Underdown, MD
11:20 am – 11:50 am
Expert Panel Discussion/Q&A: Patrick Grohar, Michael Edwards, Jane Underdown
Moderator: Emily Blauel, MD
11:50 am – 12:00 pm
Closing Remarks, Adjourn (lunch will not be provided)
Bennie Lindeque MD, PhD
PONSORS
Platinum Sponsors
Cogent Biosciences
Deciphera
Flint Animal Cancer Center
Zimmer Biomet
Gold Sponsors
Aadi Bioscience
InhibRx
Natura
Stryker
Springworks
UCHealth
Recognition Sponsor
CarboFix Orthopedics
DISCLOSURE of Relevant Financial Relationships to Learners
Rocky Mountain Sarcoma Symposium
April 17 – 18, 2026
Boulder, Colorado
Name
Janai Carr-Ascher, MD
Steve Dow, DVM, PhD
Mark Greyson, MD
Patrick Grohar, MD
Ineligible Company
Deciphera
Medical Ventures
CorImmune Therapeutics
Medartis
Endo Pharmaceuticals
OrphAI
Pharma Mar Jazz Pharmaceutical and Janssen Pharm.*
Inhibrx
Robert Maki, MD
Boehringer Ingelheim*
Deciphera
Peel Therapeutics
Exelixis
Medtronic
Rober Meguid
Steven Thorpe, MD
Breelyn Wilky, MD
Deciphera* & Inhibrix*
Springworks, Deciphera, Boehringer
Ingelheim, Daiichi Sankyo, AADI, Inhibrx & Agenus
Exelixus
Relationship
Advisor Speaker Advisor/Patent
Beneficiary Consultant Speaker
Consultant/Advisor/Stock Options
Consultant/Speaker
Research Support Recipient
Research Support Recipient/Advisor
Consultant/Advisor
Consultant/Data Safety Monitoring Board
Consultant/Stock Options
Research Support Recipient
Consultant
Consultant
Consultant
Research Support Recipient *relationship has ended
All of the relevant financial relationships listed for these individuals have been mitigated.
All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligble companies.
Definitions
An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients
Relevant financial relationships are financial relationships of any amount occurring in the past 24 months with ineligible companies if the educational content an individual can control is related to the business lines or products of the ineligible company.
3/19/26 - CJW
Evaluations and CME Certificates
Evaluations for the Rocky Mountain Sarcoma Symposium - April 17-18, 2026 will be provided electronically using Survey Monkey with the ability to claim CME credit for the sessions you’ve attended.
At the end of the symposium, please use this link or QR Code to complete the evaluation survey You must complete the evaluation to receive credit and claim your certificate The evaluation will close on Sunday May 3 at 5 pm rd Your CME certificate will be emailed on Monday May 4th
https://www.surveymonkey.com/r/RkyMtnSarcoma2026
Accreditation and Designation Statement
The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Colorado School of Medicine designates this live activity for a maximum of 11 25 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in this activity
Please contact omecme@.cuanschutz.edu if you have any questions.